NRAS and melanoma: Consistent cross-comparison to treatment with non-targeting control ASOs, the analysis of publicly available NRAS-knockout databases and the thorough in vitro and in vivo testing on cancerous and non-cancerous cells, further suggested a highly specific and targeted impact of NRAS ASOs on NRAS-mutant melanoma cells and low toxicity on NRAS-WT cells.